免疫治疗联合大分割放疗在转移性非小细胞肺癌中的分析:美国国家癌症数据库研究
该回顾性分析基于美国国家癌症数据库,纳入6383例接受免疫治疗的转移性非小细胞肺癌患者及170479例仅接受放疗未接受免疫治疗的患者,评估放疗(尤其大分割放疗)对总生存的影响。中位随访12个月,接受大分割放疗者1年总生存率59.0%,未放疗者55.7%,差异无统计学意义(HR=0.9,P=0.22);非大分割放疗者生存更差。结论提示免疫治疗联合或不联合大分割放疗生存相似,需前瞻性验证。
要点
- 免疫治疗联合大分割放疗与单纯免疫治疗相比,1年总生存无显著差异(59.0% vs 55.7%,HR=0.9,P=0.22)。
- 接受非大分割放疗(<5 Gy/次)的患者总生存显著差于未接受放疗者。
- 免疫治疗可改善接受放疗(无论分割大小)患者的总生存。
核心结论
- 在转移性非小细胞肺癌的初始治疗中,免疫治疗联合或不联合大分割放疗的患者生存相似。
研究设计与样本
- 回顾性队列分析,使用美国国家癌症数据库(NCDB),纳入6383例接受免疫治疗的转移性非小细胞肺癌患者和170479例接受放疗但未接受免疫治疗的患者。
- 大分割放疗定义为分次剂量至少5 Gy,标准分割放疗定义为分次剂量小于5 Gy。
- 采用Kaplan-Meier分析和比例风险模型,并通过逆加权法生成倾向性评分评估放疗对总生存的影响。
主要发现
- 中位随访时间为12个月。
- 接受大分割放疗的患者1年总生存率为59.0%,未接受放疗者为55.7%,差异无统计学意义(风险比=0.9,P=0.22)。
- 接受非大分割放疗的患者总生存显著差于未接受放疗者。
- 免疫治疗改善了接受放疗(无论分次剂量大小)患者的总生存。
关键数值与推荐
- 大分割放疗的分次剂量阈值为至少5 Gy。
- 总生存比较的风险比为0.9,P值为0.22。
临床怎么用
- 对于转移性非小细胞肺癌患者,免疫治疗联合大分割放疗与单纯免疫治疗生存相似,可作为临床决策参考。
- 非大分割放疗(分次剂量<5 Gy)可能与更差生存相关,选择放疗方案时需谨慎。
局限性
- 该研究为假设生成性回顾性分析,存在回顾性研究固有的选择偏倚和混杂因素。
- 需要进一步前瞻性研究验证免疫治疗联合大分割放疗的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Metastatic non-small cell lung cancer (NSCLC) is associated with an exceedingly poor prognosis. Recent advances in immunotherapy offer promise in enhancing overall survival (OS) in these patients. Preclinical evidence suggests that radiotherapy (RT), especially when offered in a high-dose per fraction hypofractionated RT (HRT) as in stereotactic ablative body radiotherapy (SABR), may augment the efficacy of immunotherapy. We aimed to assess the role of RT in patients with metastatic NSCLC receiving immunotherapy in a national hospital-based database. METHODS: Using the National Cancer Database (NCDB), we identified 6,383 patients treated with immunotherapy for metastatic NSCLC and 170,479 patients treated with RT but without immunotherapy. Patients receiving fractional doses of at least 5 Gy were designated as having received HRT, doses <5 Gy/fraction, were deemed standard fractionation (SFRT). The Kaplan-Meier analysis and proportional hazards modeling were performed, and propensity scores were generated via an inverse weighting method to evaluate the impact of RT on OS in this cohort. RESULTS: The median follow-up of the cohort is 12 months. Patients receiving HRT had numerically improved 1-year OS (59.0%) compared to those not receiving RT (55.7%), however this was not statistically significant (hazard ratio = 0.9, p = 0.22). Patients receiving non-HRT RT did substantially worse than those receiving no RT. Immunotherapy improved OS in patients receiving RT regardless of fraction size. CONCLUSIONS: This hypothesis-generating retrospective analysis suggests that patients treated with immunotherapy with or without HRT in the upfront treatment of metastatic NSCLC experience similar survival. Further prospective evaluation of this combination should be undertaken in an attempt to maximize survival in this challenging disease.
引用
- Bates JE, Morris CG, Milano MT, et al. Immunotherapy with hypofractionated radiotherapy in metastatic non-small cell lung cancer: An analysis of the National Cancer Database. Radiother Oncol. 2019. PMID: 31252297. doi:10.1016/j.radonc.2019.06.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。